The Medicines Company

The Medicines Company
Name	The Medicines Company
Foundation	1996
Founder	Clive Meanwell
Defunct	2020
Fate	Acquired by Novartis
Location	Parsippany, New Jersey, U.S.
Industry	Pharmaceuticals
Key people	Clive Meanwell (CEO), William Hawkins (Chairman)

The Medicines Company. It was a global pharmaceutical firm focused on acquiring, developing, and commercializing therapies for serious medical conditions, particularly in the acute and intensive care hospital setting. Founded in 1996, the company became known for its strategic approach to in-licensing late-stage assets and navigating complex development and commercialization pathways. Its operational history concluded in 2020 following its acquisition by the Swiss multinational Novartis.

History

The company was established in 1996 by former Ciba-Geigy executive Clive Meanwell. Its initial strategy centered on in-licensing and developing hospital-based pharmaceuticals, with an early focus on the anticoagulant angiotensin II receptor blocker. A significant early milestone was the 2000 acquisition of the rights to the intravenous anticoagulant bivalirudin from Biogen, which became its flagship product marketed as Angiomax. The company conducted its initial public offering on the NASDAQ in 2000, raising capital to fund further development. Throughout the 2000s and 2010s, it expanded its portfolio through targeted acquisitions and advanced several candidates through clinical trials, maintaining its headquarters in Parsippany, New Jersey.

Products

Its portfolio was dominated by hospital-administered therapeutics. The cornerstone product was bivalirudin (Angiomax), a direct thrombin inhibitor used as an anticoagulant in patients undergoing percutaneous coronary intervention. Another key product was the antibiotic oritavancin, acquired from Targanta Therapeutics and marketed as Orbactiv for acute bacterial skin infections. The company also developed and marketed Ionsys, a patient-controlled fentanyl iontophoretic transdermal system for acute postoperative pain, which was originally developed by Alza Corporation. Its late-stage pipeline included inclisiran, a novel therapy for hypercholesterolemia developed using Alnylam Pharmaceuticals' RNA interference platform.

Acquisitions and collaborations

Growth was heavily driven by strategic transactions. A major early deal was the 2009 acquisition of Targanta Therapeutics, which brought oritavancin into its pipeline. In 2013, it acquired Ionsys from Incline Therapeutics. The company formed a pivotal collaboration with Alnylam Pharmaceuticals in 2013 to develop inclisiran, investing significantly in the RNA interference technology. Further expanding its cardiovascular portfolio, it acquired the global rights to the investigational drug MDCO-216, a high-density lipoprotein mimetic, from Esperion Therapeutics in 2015. It also entered into a partnership with Melinta Therapeutics for the commercialization of certain antibiotics.

Clinical trials and research

The company was actively engaged in late-stage clinical development. It conducted the landmark CHAMPION PHOENIX trial for cangrelor, which led to its approval by the U.S. Food and Drug Administration. Extensive research was dedicated to the ORION clinical trial program for inclisiran, which demonstrated robust and durable lowering of low-density lipoprotein cholesterol with biannual dosing. It also managed the development program for ANG-3777, a hepatocyte growth factor mimetic being studied for cardiac and renal complications. Research efforts often focused on demonstrating superior outcomes in acute care settings compared to existing standards of care.

Corporate affairs

The company was led for most of its history by founder Clive Meanwell; later, former Medtronic CEO William Hawkins served as Chairman. Its corporate strategy emphasized maximizing the value of acquired assets through focused development and targeted marketing to hospital specialists. Following the positive data from the ORION trials, the company undertook significant financial and strategic preparations for the potential launch of inclisiran, which attracted the attention of larger pharmaceutical firms. This ultimately led to negotiations with Novartis, culminating in the acquisition agreement announced in late 2019.

Legal and patent issues

It was involved in significant patent litigation and regulatory challenges. A prolonged legal battle with Hospira, a unit of Pfizer, concerned patent protections for bivalirudin and its manufacturing process. The company also faced a patent dispute with Sanofi and Regeneron Pharmaceuticals related to the PCSK9 inhibitor class, into which inclisiran fell. Furthermore, it navigated complex issues surrounding the U.S. Food and Drug Administration approval and subsequent withdrawal from the market of the Ionsys system due to manufacturing concerns, before successfully re-launching it with a new risk management program.

Category:Pharmaceutical companies of the United States Category:Companies based in Morris County, New Jersey Category:Companies listed on NASDAQ Category:Pharmaceutical companies established in 1996